clinical trials completed
effect size on WOMAC pain in higher-pain patients (Phase 2b)
patented key markets for liquid formulation
AKL’s primary focus is osteoarthritis, where the need for a well-tolerated oral treatment remains high. We’ve been concentrating our resources on APPA, which has been studied in a Phase 1 study in the UK, a Phase 2a study in Denmark and a Phase 2b dose-ranging study in Denmark and Hong Kong.
The clinical data show a consistent pattern. APPA has been generally well tolerated, efficacy has been dose-related, and benefit has been greatest in patients with higher baseline pain. This gives a defined patient population for the next stage of development.
The next step is an optimized formulation. Patented liquid capsules are designed to make better use of each dose, ahead of a Phase 2/3 program in the patients most likely to benefit.
AKL is seeking a partner to take APPA forward. Detailed data are available under confidentiality. Please contact us.